VYST.OQBVystar CORP
10-Q: Vystar Corporation Reports Mixed Results in Q2 2024 Amidst Restructuring Efforts
Sentiment:
Quarterly Report
Vystar Corporation's Q2 2024 results show a decrease in revenue and a net loss, but also a significant reduction in losses from discontinued operations as the company focuses on its core product lines.
Capital raiseThe company plans to raise capital with common stock subscription issuances.The company may need to seek additional financing of equity or debt if it cannot achieve projected revenue.
Worse than expectedThe company's revenue decreased significantly, indicating a worse than expected performance.The company's gross profit decreased substantially, indicating a worse than expected performance.The company's net loss, while reduced, is still significant, indicating a worse than expected performance.
Summary
- Vystar Corporation reported a net loss of $288,141 for the three months ended June 30, 2024, compared to a net loss of $521,467 for the same period in 2023.
- Revenue for the quarter was $38,069, a slight increase from $36,126 in the prior year.
- The company's gross profit decreased to $15,137 from $30,213 year-over-year, due to internal sales reserve adjustments.
- Operating expenses decreased to $265,146 from $319,150, primarily due to reduced salaries and commissions.
- Interest expense increased significantly to $36,187 from $11,181 due to new debt and amortization of debt discount.
- Losses from discontinued operations decreased substantially to $1,945 from $221,349, reflecting the winding down of Rotmans operations.
- For the six months ended June 30, 2024, the net loss was $662,859, compared to $1,798,543 in 2023.
- Six-month revenue decreased to $75,676 from $446,033, due to internal reorganization and decreased sales allowances.
- Gross profit for the six months was $35,324, down from $363,422 in the prior year.
- Operating expenses for the six months decreased to $622,571 from $703,076.
- Interest expense for the six months increased to $44,276 from $21,518.
- Losses from discontinued operations for the six months decreased to $31,336 from $1,437,371.
Sentiment
Score: 3
Explanation: The document presents a mixed picture with some positive developments, such as reduced losses, but significant concerns remain regarding revenue, profitability, and the company's ability to continue as a going concern. The material weaknesses in internal controls are also a major concern.
Positives
- The company's net loss decreased significantly in both the three and six-month periods, indicating improved financial performance.
- Operating expenses were reduced due to lower salaries and commissions.
- Losses from discontinued operations decreased substantially, reflecting the winding down of Rotmans operations.
- The company is focusing on its core product lines, RxAir and Vytex, which may lead to improved future performance.
Negatives
- Revenue decreased significantly for the six-month period, indicating challenges in sales.
- Gross profit decreased substantially in both the three and six-month periods due to internal sales reserve adjustments.
- Interest expense increased significantly due to new debt and amortization of debt discount.
- The company has a history of losses and negative cash flow, raising concerns about its ability to continue as a going concern.
Risks
- The company has a history of significant losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern.
- The company's future success depends on obtaining sufficient financing and achieving adequate revenue levels.
- The company may need to curtail or reorient operations if it cannot achieve projected revenue or obtain additional financing.
- The company is subject to various risks, including market acceptance of its products, competition, and economic factors.
- The company has identified material weaknesses in its internal control over financial reporting.
Future Outlook
Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units and Vytex license fees, and stock issuances. There is no assurance that the company will achieve projected revenue levels or obtain additional financing.
Management Comments
- Jamie Rotman took over as CEO to refocus the Company on Vystar's two main product lines, RxAir and Vytex.
- Management plans to finance future operations using cash on hand, increased revenue from RxAir air purifier sales and Vytex license fees.
- Management expects to strengthen internal control during 2024 by developing stronger business and financial processes for accounting for transactions.
Industry Context
The company operates in the air purification and natural rubber latex industries, which are subject to market trends, competition, and regulatory changes. The company's focus on its core product lines and its efforts to expand into new markets align with industry trends towards innovation and sustainability.
Comparison to Industry Standards
- The company's revenue decline is concerning compared to industry growth in air purification and natural rubber latex.
- The company's gross profit margins are significantly lower than industry averages, indicating potential issues with pricing or cost management.
- The company's operating expenses are high relative to its revenue, suggesting a need for cost-cutting measures.
- The company's reliance on related party debt and advances is not typical for publicly traded companies and may raise concerns about financial stability.
- The company's material weaknesses in internal control over financial reporting are a significant concern and need to be addressed promptly.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President, Chief Executive Officer, and Chief Financial Officer | Steven Rotman | Jamie Rotman | 2023-12-21 | Succession and internal reorganization |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses | The company identified material weaknesses in its internal control over financial reporting, including lack of segregation of duties, inadequate record keeping, and lack of a formal CFO position. | 2024-06-30 | These weaknesses could lead to material misstatements in the financial statements and require significant remediation efforts. |
Legal Proceedings
- The company is involved in ongoing litigation with EMA Financial, with a cross-appeal filed in the United States Court of Appeals for the Second Circuit.
Related Party Transactions
- The company has significant related party transactions with officers, directors, and their affiliated entities, including consulting agreements, debt, and advances.
- Jamie Rotman, the President, CEO, and CFO, has an employment agreement with the company, including compensation in stock and cash.
- Blue Oar Consulting, Inc., owned by Gregory Rotman, provides business consulting services to the company.
- Steven Rotman, a former officer and director, has a significant stock subscription payable balance and reimbursable expenses payable.
Stakeholder Impact
- Shareholders are impacted by the company's net losses and the uncertainty surrounding its ability to continue as a going concern.
- Employees are impacted by the company's restructuring efforts and potential cost-cutting measures.
- Customers may be impacted by the company's focus on core product lines and potential changes in product offerings.
- Creditors are impacted by the company's debt levels and its ability to repay its obligations.
- Suppliers may be impacted by the company's financial challenges and potential changes in purchasing patterns.
Next Steps
- The company plans to introduce new RxAir products and license Vytex NRL raw material.
- The company will focus on developing stronger business and financial processes for accounting for transactions.
- The company will continue to pursue legal proceedings related to EMA Financial.
Key Dates
| Date | Description |
|---|---|
| 2004-12-31 | Vystar adopted a stock option plan. |
| 2009-04-30 | Vystar's Board of Directors authorized an increase in the number of shares to be issued under the stock option plan. |
| 2013-05-02 | Vystar began a private placement offering to sell Series A Cumulative Convertible Preferred Stock. |
| 2018-12-31 | Vystar issued shareholder contingently convertible notes payable. |
| 2019-05 | Vystar acquired the assets of Fluid Energy Conversion Inc. |
| 2021-08-17 | Vystar issued a contingently convertible promissory note to Jamie Rotman. |
| 2022-04-11 | Vystar amended its Articles of Incorporation to add the terms of a Series B Cumulative Convertible Preferred Stock. |
| 2022-07-08 | Vystar amended its Articles of Incorporation to add the terms of a Series C Cumulative Convertible Preferred Stock. |
| 2022-12-14 | Rotmans closed its showroom. |
| 2023-12-21 | Jamie Rotman was appointed as President of Vystar. |
| 2024-01-01 | Employment Agreement with Jamie Rotman was made retroactive to this date. |
| 2024-06-01 | Vystar entered into a term convertible promissory note with Blue Oar Consulting, Inc. |
| 2024-06-30 | End of the reporting period for the quarterly report. |
| 2024-07-22 | Vystar entered into an Employment Agreement with Jamie Rotman. |
| 2024-10-29 | Date of filing of the quarterly report. |
Keywords
Vystar Corporation, RxAir, Vytex, air purification, natural rubber latex, financial results, Q2 2024, discontinued operations, net loss, revenue, operating expenses, internal control, going concern
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.